GLP-1 and Metformin Together: Safety and Side Effects

You are on metformin for type 2 diabetes or prediabetes. Your blood sugar control is partially managed but not optimal. You have read about GLP-1 medications for either better glucose management or weight loss. The question is straightforward: can you take both medications at the same time, or do you need to choose one?

The answer is yes. GLP-1 medications and metformin are commonly prescribed together, and they are not redundant. They work through different mechanisms. But combining them does require understanding what happens when you layer two medications that can both affect appetite, digestion, and glucose metabolism. Here is what you need to know to make an informed decision with your provider.

How Metformin Works

Metformin is a first-line oral medication for type 2 diabetes. It works by reducing how much glucose your liver produces (hepatic glucose production) and improving how sensitive your cells are to insulin. In other words, it helps your body use the insulin it already makes more efficiently.

Metformin does not trigger your pancreas to release more insulin. That is why it rarely causes hypoglycemia (dangerously low blood sugar) when used alone. It makes your existing insulin work better and reduces the glucose your liver releases into your bloodstream.

Metformin also has modest weight loss effects. In the Diabetes Prevention Program, people taking metformin lost about 2 percent of their body weight on average, compared with almost none on placebo^[2]. That is far less than what GLP-1 medications produced in their trials, but it is a documented effect.

How GLP-1 Medications Work

GLP-1 medications work through a completely different mechanism. They are glucagon-like peptide-1 receptor agonists: they mimic a hormone your body makes naturally in response to food. When you eat, GLP-1 tells your pancreas to release insulin, but only when blood sugar is actually elevated. It also slows digestion (gastric emptying), which means food moves through your stomach and intestines more slowly, and it reduces appetite signaling in your brain.

The weight loss seen with GLP-1 medications in clinical trials is substantially greater than with metformin, with averages typically in the range of 5 to 15 percent of body weight, depending on the medication, dose, and population studied. People with type 2 diabetes tend to lose less than people without it: in the STEP 2 trial of adults with type 2 diabetes, semaglutide 2.4 mg produced an average weight loss of 9.6 percent at 68 weeks, compared with 3.4 percent on placebo^[4]. Results vary, and trial averages are not a prediction for any individual.

How They Work Together

GLP-1 medications and metformin are complementary, not redundant. They hit different targets in the glucose-control system.

Metformin says: “Make sure your liver is not overproducing glucose, and make sure your cells are listening to the insulin you already have.”

GLP-1 says: “Release insulin at the right time when blood sugar goes up, and slow down your appetite and digestion so you eat less and feel fuller faster.”

This combination approach is exactly what major diabetes treatment guidelines recommend^[1]. The American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) both support adding GLP-1 medications to existing metformin therapy in patients who need additional blood sugar control or weight management.

How they work differently vs. how they work together

Weight Loss With Both Medications

If you are taking metformin for type 2 diabetes and considering a GLP-1 program for weight management, combining them is a common approach.

Metformin’s effect on weight is modest: about 2 percent of body weight on average in the Diabetes Prevention Program^[2]. GLP-1 medications produced substantially more in clinical trials that lasted more than a year (68 weeks in STEP 2^[4]), with results depending on the medication and dose. The combination brings together metabolic support from metformin and the appetite and digestion changes from the GLP-1. Results vary.

GLP-1 medications are also studied and prescribed for people who do not take metformin, so metformin is not required. But if you are already on metformin for diabetes management, providers often continue it when a GLP-1 is added, because the two work on different targets.

Hypoglycemia Risk: The Good News

One of the most common concerns patients have when combining medications is whether their blood sugar might drop too low (hypoglycemia).

The straightforward answer: neither metformin alone nor GLP-1 alone causes hypoglycemia in most patients. Metformin does not trigger insulin release on its own; it makes your existing insulin more effective. GLP-1 only triggers insulin release when your blood sugar is already elevated, which is a built-in safety mechanism.

The combination of these two specific drugs does not significantly increase hypoglycemia risk on its own. Hypoglycemia becomes a real concern only when you add insulin or a sulfonylurea (insulin secretagogues, medications that force your pancreas to release insulin regardless of blood sugar levels). If you are on one of those medications in addition to metformin and GLP-1, your provider will monitor you more closely.

GI Side Effects: When They Overlap

This is where the combination deserves careful attention. Both metformin and GLP-1 medications can cause gastrointestinal side effects.

Metformin commonly causes:

• Nausea (especially when starting)
• Diarrhea or loose stools
• Abdominal discomfort or bloating
• Reduced appetite

GLP-1 medications commonly cause:

• Nausea (often pronounced during dose escalation)
• Constipation or diarrhea (varies by person and medication)
• Reduced appetite (intentional therapeutic effect)
• Abdominal discomfort

When you combine both medications, GI side effects can be additive. The nausea might be more pronounced. Diarrhea or constipation might be more difficult to manage. Some patients experience significant appetite suppression and find it hard to eat enough.

However, this is manageable. Here is how:

Start low and go slow: If you are adding a GLP-1 to existing metformin therapy, your provider will start the GLP-1 at the lowest dose and escalate slowly over weeks. This gives your body time to adapt to the GLP-1 without compounding the metformin side effects you may have already adjusted to.

Meal timing: Eat smaller, more frequent meals rather than three large ones. This helps manage nausea and ensures you get adequate nutrition even with reduced appetite.

GI support: Some people find over-the-counter remedies like ginger, peppermint, or an antacid helpful; check with your provider or pharmacist before adding one. Some people also find that spreading metformin doses (taking it with breakfast and dinner instead of all at once) reduces GI symptoms.

Communication with your provider: Report GI symptoms early. If nausea or diarrhea is severe, your provider may adjust the GLP-1 dose, change the timing of your metformin dose, or explore alternative formulations. For detailed strategies, see our guide on managing GLP-1 nausea.

Vitamin B12 and Long-Term Use

Long-term metformin use is linked to lower vitamin B12 levels, and the risk rises with years of use^[3]. In the Diabetes Prevention Program Outcomes Study, low or borderline-low B12 was found in about 20 percent of people on metformin at 13 years, compared with about 16 percent on placebo. Metformin is thought to interfere with B12 absorption in the small intestine.

GLP-1 medications slow gastric emptying, which means food moves through your stomach more slowly. Whether this affects B12 absorption has not been well studied.

If you are on both medications long-term, your provider may:

• Order a baseline B12 level when you start the GLP-1
• Recheck B12 levels periodically
• Recommend B12 supplementation if levels drop

Most patients do not develop symptomatic B12 deficiency, but monitoring is straightforward and important. For more detail on vitamins and supplementation on GLP-1, see our guide on vitamins and supplements on GLP-1 medications.

Special Situations: Context Matters

If you have type 2 diabetes: Metformin is usually continued when a GLP-1 is added. The combination is standard care. Your provider may reduce or stop metformin if your blood sugar runs too low on your overall regimen or if you develop a contraindication (for example, kidney function that declines below the level the metformin label allows).

If you are taking metformin for prediabetes or metabolic health (not diabetes): The decision to continue metformin alongside a GLP-1 program is less clear-cut. Some providers prefer to simplify the medication regimen to just the GLP-1. Others continue metformin for its additional metabolic benefits. This is a conversation to have with your provider based on your specific health history.

If you are taking metformin for weight loss only (not for blood sugar management): This is less common, but it happens. Metformin is not FDA-approved for weight loss, and its weight loss effects are modest. If this is your situation, your provider may recommend stopping metformin and using a GLP-1 medication alone, since GLP-1 medications produced much larger weight loss in clinical trials and does not require ongoing B12 monitoring.

If you are on metformin and other medications: Inform your provider of all medications and supplements. GLP-1 medications can affect how your body absorbs some oral medications (because of the slowed gastric emptying), and your provider may need to adjust dosing or timing.

The Clinical Decision-Making Process

The decision to combine GLP-1 and metformin, or to use one or the other, is a clinical decision made by your provider. Here is what that process typically looks like:

1. Review your medical history: Your provider will look at your current blood sugar control, kidney function, any history of pancreatitis or gallbladder disease, and all current medications.

2. Discuss your goals: Are you managing type 2 diabetes, prediabetes, or weight management? What outcomes matter most to you?

3. Evaluate the evidence: If you have type 2 diabetes and are not at goal on metformin alone, GLP-1 is a well-supported next step. If you are on metformin and want significant weight loss, adding a GLP-1 is also a strong option.

4. Consider side effects: Your provider will weigh the risks of GI side effects from combining both medications against the benefits of better glucose control and weight loss.

5. Determine the right dose and timing: If a GLP-1 is appropriate, your provider will prescribe a starting dose and an escalation schedule that works with your existing metformin therapy.

6. Plan for monitoring: If you are on both medications, your provider will want to check in regularly (typically at 4 to 6 weeks after starting the GLP-1, then every 3 to 6 months) to monitor blood sugar, tolerability, and side effects.

At most telehealth programs, a licensed provider reviews your health history and current medications and decides whether a prescription is appropriate. If you take metformin, ask these questions before you choose a program:

• Who manages your diabetes care? Ask whether the program’s prescriber will coordinate with the provider who prescribes your metformin, and whether they will need recent lab results such as A1C and kidney function.
• Are labs included or billed separately? Some programs include baseline and follow-up labs; others bill separately or ask you to get them through your own provider.
• How are dose increases handled? Ask how often the prescriber checks in during escalation and what happens if GI side effects make it hard to move to the next dose.
• Is the medication brand-name or compounded? Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality.
• What is the total cost? Compare medication, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms.

Key Takeaways

• GLP-1 and metformin work through different mechanisms and are commonly prescribed together in diabetes management.
• The combination does not significantly increase hypoglycemia risk when used without insulin or sulfonylureas.
• GI side effects can be additive, especially when starting or escalating the GLP-1. This is manageable with slow dose escalation, meal adjustments, and good communication with your provider.
• Long-term metformin use may affect B12 absorption. Whether GLP-1 medications add to this has not been well studied. Periodic monitoring is recommended.
• The decision to continue, reduce, or stop metformin when starting a GLP-1 is clinical and depends on your specific health situation. Never stop metformin without guidance from the provider who prescribed it.
• Your provider will evaluate your complete health picture, including blood sugar control, kidney function, side effect tolerance, and personal goals, before making any changes to your medication regimen.

If you are on metformin and considering a GLP-1, bring your full medication list and recent lab results (A1C and kidney function) to the conversation with the provider who manages your diabetes or the program you choose.

Citations

[1] American Diabetes Association Professional Practice Committee. “9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.” Diabetes Care 2026;49(Supplement 1):S183-S215. https://pubmed.ncbi.nlm.nih.gov/41358900/ (Guideline support for combining glucose-lowering medications, including GLP-1 medications with metformin.)

[2] Diabetes Prevention Program Research Group. “Long-term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study.” Diabetes Care 2012;35(4):731-737. https://pubmed.ncbi.nlm.nih.gov/22442396/ (Average weight loss of about 2% with metformin vs 0.02% with placebo.)

[3] Aroda VR, et al. “Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.” The Journal of Clinical Endocrinology & Metabolism 2016;101(4):1754-1761. https://pubmed.ncbi.nlm.nih.gov/26900641/ (Low and borderline-low B12 more common with long-term metformin use.)

[4] Davies M, et al. “Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.” Lancet 2021;397(10278):971-984. https://pubmed.ncbi.nlm.nih.gov/33667417/ (Average weight loss of 9.6% with semaglutide 2.4 mg vs 3.4% with placebo at 68 weeks in adults with type 2 diabetes.)